Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 15, 2012-08 ,pp. : 1713-1719

Bentham Science Publishers

Access to resources Recommend Favorite

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 672-680

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime—a population study in 25 elderly patients

By Urien S.   Laurent N.   Barre J.   Druguet M.   Bouvier D’yvoire M.   Maire P.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 1, 2004-03 ,pp. : 11-16

Springer Publishing Company

Access to resources Recommend Favorite

A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer

By Murren John   Modiano Manuel   Kummar Shivaani   Clairmont Caroline   Egorin Merrill   Chu Edward   Sznol Mario  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 123-135

Springer Publishing Company

Access to resources Recommend Favorite

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer

By Ajani Jaffer   Takimoto Chris   Becerra Carlos   Silva Alejandro   Baez Luis   Cohn Allen   Major Pierre   Kamida Makio   Feit Kevie   Jager Robert  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 479-484

Springer Publishing Company

Access to resources Recommend Favorite